CareDx, Inc.
CDNA Healthcare Diagnostics & Research
CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 52.2%, EPS grew 1,443.8% and free cash flow grew 223.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow CDNA
CareDx, Inc. (CDNA) P/E ratio
As of 16 October 2026, CareDx, Inc. (CDNA) trades at a P/E ratio of 29.7×. Over the past ten years it has ranged from 0.0× (June 2026) to 32.5× (October 2026); the current reading is higher than 100% of that period. That is below the Diagnostics & Research industry median of 35.6× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 21.2× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 13.3× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 11.2× | (38.82%) |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| WGS GeneDx Holdings Corp. compare | n/m |
| RDNT RadNet, Inc. compare | n/m |
| NEO NeoGenomics, Inc. compare | n/m |
| GRAL GRAIL, Inc. compare | n/m |
| ADPT Adaptive Biotechnologies Corporation compare | n/m |
| CDNA CareDx, Inc. | 29.7× |
| VCYT Veracyte, Inc. compare | 29.9× |
| SHC Sotera Health Company compare | 31.4× |
| BLLN BillionToOne, Inc. compare | 95.0× |
| Diagnostics & Research industry median | 35.6× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)